© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
October 06, 2022
Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.
The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.
October 05, 2022
Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.
October 04, 2022
Rocket Pharma presented updated data from adult and pediatric patients at the 2022 HFSA meeting.
October 03, 2022
Solid has also pivoted from developing SGT-001 to SGT-003 for treating Duchene muscular dystrophy.
Participants in the AAVIATE trial had up to an 85% decrease in treatment burden 6 months after treatment with RGX-314.
October 01, 2022
Disease-free survival was 56% in 105 participants over 3 years.
September 30, 2022
Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.
Verismo plans to initiate a phase 1, first-in-human trial of SynKIR-110 in the first quarter of 2023.
September 29, 2022
SRP-9001 has shown safety and efficacy across multiple studies compared to controls, with additional efficacy data expected in 2024 from the EMBARK trial.